Figure 7.
CD5-scFv-CAR NK-92 cells are superior to CD5-VLR-CAR NK-92 cells in delaying disease progression and improving survival in a T-ALL xenograft mouse model. (A) NSG mice were injected with 2 × 106 luciferase-expressing Jurkat T cells intravenously on day 0. Treatment was started 7 d after tumor injection with each mouse receiving a total of 4 treatments on days 7, 11, 14 and 18. Mice were assigned to 4 different treatment groups – saline, naïve NK-92, CD5-VLR-CAR NK-92 or CD5-scFv-CAR NK-92. A dose of 107 cells per mouse were administered at each treatment time. Bioluminescence imaging was performed every seven days to monitor tumor burden. (B) Total bioluminescence from Jurkat T cells on days 14, 21, and 28 post tumor injection. A significant decrease (p < 0.05) in tumor burden is observed in the CD5-scFv-CAR NK-92 group. Errors bars represent standard deviations. (C) Kaplan-Meier survival curves showing overall survival. Mice treated with CD5-scFv-CAR NK-92 cells showed significant increased survival (p < 0.05) when compared to all other treatment groups. Mice treated with CD5-VLR-CAR NK-92 cells did not have a significant advantage over saline and naïve NK-92 treatment groups.